US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

50.92

+0.10190.20%

Post-market: 50.89-0.0309-0.06%16:05 EDT

Volume:2.74K

Turnover:139.47K

Market Cap:25.46M

PE:- -

High:50.92

Open:50.84

Low:50.84

Close:50.82

Loading ...

Overview Company News Filings

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSF/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":50.9209,"timestamp":1744920000000,"preClose":50.819,"halted":0,"volume":2742,"hourTrading":{"tag":"盘后","latestPrice":50.89,"preClose":50.9209,"latestTime":"16:05 EDT","volume":2,"amount":101.8418,"timestamp":1744920313821},"delay":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Market Closed","change":0.1019,"latestTime":"04-17 16:00:00 EDT","open":50.84,"high":50.9209,"low":50.84,"amount":139469.3583,"amplitude":0.001592,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":50.819,"sharesOutstanding":500000,"nav":50.919731,"aum":25459850,"bidAskSpread":0.001349,"preHourTrading":{"tag":"盘前","latestPrice":50.819,"preClose":50.819,"latestTime":"08:02 EDT","volume":8,"amount":406.552,"timestamp":1744891358272},"postHourTrading":{"tag":"盘后","latestPrice":50.89,"preClose":50.9209,"latestTime":"16:05 EDT","volume":2,"amount":101.8418,"timestamp":1744920313821},"volumeRatio":0.3635254778799937},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3635254778799937,"shares":500000,"dividePrice":0.78061,"high":50.9209,"amplitude":0.001592,"preClose":50.819,"low":50.84,"week52Low":47.7503,"pbRate":"--","week52High":60.63,"institutionHeld":0,"latestPrice":50.9209,"eps":0,"divideRate":0.01533,"volume":2742,"delay":0,"ttmEps":0,"open":50.84,"prevYearClose":54.8761,"prevWeekClose":50.7,"prevMonthClose":51.5505,"prevQuarterClose":51.5505,"fiveDayClose":50.55,"twentyDayClose":52.06,"sixtyDayClose":56.7724},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2480732984","title":"QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2480732984","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480732984?lang=en_us&edition=fundamental","pubTime":"2024-11-04 14:30","pubTimestamp":1730701800,"startTime":"0","endTime":"0","summary":"QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successf","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/04/2973707/8690/en/QIAGEN-receives-FDA-clearance-of-QIAstat-Dx-meningitis-encephalitis-panel-to-support-emergency-diagnostics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2433249047.HKD","BK4121","LU2125909593.SGD","CSF","LU2125909247.SGD","LU1923622614.USD","QGEN"],"gpt_icon":0},{"id":"2479339220","title":"Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain","url":"https://stock-news.laohu8.com/highlight/detail?id=2479339220","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479339220?lang=en_us&edition=fundamental","pubTime":"2024-10-31 22:00","pubTimestamp":1730383200,"startTime":"0","endTime":"0","summary":"Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s disease. ROCHESTER, N.Y., Oct. 31, 2024  -- Vaccinex  today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease.Finally, investors will be aware of concerns regarding damage to vascular integrity of brain tissue and the risk of inflammation and hemorrhage due to treatment with antibodies to Abeta amyloid. We have not seen evidence of such effects for treatment with pepinemab antibody. On the contrary, employing a human Brain-Chip model, we were able to demonstrate that damage caused by toxic aggregates of alpha synuclein can be inhibited or reversed by treatment with pepinemab. The results of similar analysis of damage caused by Abeta amyloid in the presence or absence of anti-Abeta antibody will be reported soon.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H5isOUlBYvEUdGC7eqGawg--~B/aD01MDI7dz0xMDkxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dfb2768860a83c395690190ef8a3510f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H5isOUlBYvEUdGC7eqGawg--~B/aD01MDI7dz0xMDkxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/dfb2768860a83c395690190ef8a3510f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaccinex-reports-findings-signal-ad-140000619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0354030511.USD","LU0320765646.SGD","CSF","LU0820562030.AUD","LU1914381329.SGD","BK4585","BK4534","BK4139","LU0820561909.HKD","BK4581","LU0868494617.USD","LU1093756168.USD","LU0823411888.USD","LU1989772923.USD","LU1551013342.USD","BK4568","BK4533","IE00BKVL7J92.USD","LU0689472784.USD","LU0823434740.USD","LU1989772840.SGD","BK4504","LU1496350171.SGD","BK4550","LU1674673428.USD","LU1674673691.USD","VCNX","MCI","LU1929549753.HKD","BK4566","LU1093756325.SGD","LU1778281490.HKD","IE00BWXC8680.SGD","LU1551013425.SGD","LU0079474960.USD","BK4083","LU0943347566.SGD","IE00BSNM7G36.USD","LU0354030438.USD","LU1162221912.USD","SG9999001440.SGD","LU2756315318.SGD","LU1496350502.SGD","BK4567","HD","LU0868494708.USD","LU0820561818.USD","LU0234572021.USD","BK4588","LU2756315664.SGD"],"gpt_icon":0},{"id":"2479208575","title":"Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2479208575","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479208575?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:00","pubTimestamp":1730286000,"startTime":"0","endTime":"0","summary":"– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be prese","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/30/2971572/0/en/Arvinas-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","LU0225771236.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999013999.USD","LU0234572021.USD","IE0002270589.USD","SG9999011175.SGD","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","BK4568","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU0225284248.USD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","LU1066053197.SGD","CSF","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","LU1883839398.USD","BK4007","IE00B19Z3581.USD","BK4588","BK4534","LU0321505868.SGD","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2479271966","title":"Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479271966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479271966?lang=en_us&edition=fundamental","pubTime":"2024-10-30 18:14","pubTimestamp":1730283240,"startTime":"0","endTime":"0","summary":"Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of particip","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/30/2971504/0/en/Lexeo-Therapeutics-Announces-Positive-Interim-Data-for-LX1001-First-Ever-Gene-Therapy-to-Impact-the-Underlying-Genetic-Cause-of-APOE4-Associated-Alzheimer-s-Disease-at-the-Clinical.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARIA","MCI","BK4139","CSF","GENE","LXEO","BK4121"],"gpt_icon":0},{"id":"2479258143","title":"Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2479258143","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479258143?lang=en_us&edition=fundamental","pubTime":"2024-10-30 02:36","pubTimestamp":1730227012,"startTime":"0","endTime":"0","summary":"On Tuesday, Coya Therapeutics, Inc.  released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease.The data was shared at the Clinical Trials on Alzheimer’s Disease Conference .The study met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients with Alzheimer’s.Also Read: EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases. LD IL-2 showed targeted biological activity. Additionally, the q4wks regimen led to significant improvements  in cerebrospinal fluid  soluble Aβ42 levels, an indicator of amyloid pathology.However, the company said that the q2wks group, representing the higher total dose cohort, did not exhibit benefits in exploratory endpoints.The company will likely advance LD IL-2 q4wks.This cognitive effect was not observed in the LD IL","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9b7J0yyZ459Dk3tzGCqVRA--~B/aD01NzQ7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/e0b14ce53415bbfc1505fe19089ea725","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9b7J0yyZ459Dk3tzGCqVRA--~B/aD01NzQ7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/e0b14ce53415bbfc1505fe19089ea725"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-high-dose-interleukin-183652461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","COYA","SSI","CSF"],"gpt_icon":0},{"id":"2479540354","title":"Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas","url":"https://stock-news.laohu8.com/highlight/detail?id=2479540354","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479540354?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:30","pubTimestamp":1730201400,"startTime":"0","endTime":"0","summary":"Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and discuss its plan for continued clinical development Company","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/29/2970697/0/en/Plus-Therapeutics-Showcases-Leptomeningeal-Metastases-Programs-at-the-2024-SNO-Annual-Meeting-in-Houston-Texas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4202","BK4135","NCI","BK4139","CSF","CNS"],"gpt_icon":0},{"id":"2479474317","title":"Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479474317","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479474317?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:30","pubTimestamp":1730197800,"startTime":"0","endTime":"0","summary":"Study met Primary and Secondary Endpoints for Safety and Regulatory T cell  Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further evidence of target engagement. Exploratory Endpoints demonstrated cognitive stabilization on treatment vs. cognitive declines on placebo for LD IL-2 dosing every 4 weeks , which was associated with significant improvement in cerebrospinal fluid  soluble Aβ42 levels and stabilized CSF Neurofilament Light Chain . Study supports and increases confidence in Treg modulation strategies in neurodegenerative conditions and in advancing LD IL-2 q4wks and LD IL-2 q4wks combination strategies  in AD and other related diseases. Of the 38 total participants, 22 were randomized in a 1:1 ratio to receive either 5 days of LD IL-2   or placebo ever","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-announces-positive-results-103000665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4127","LU1169589451.USD","LD","BK4023","LU1169590202.USD","COYA","BK4139","CSF","PD","MFI","LENZ"],"gpt_icon":1},{"id":"2476101976","title":"Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2476101976","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476101976?lang=en_us&edition=fundamental","pubTime":"2024-10-18 00:07","pubTimestamp":1729181220,"startTime":"0","endTime":"0","summary":"– Relapse-free/progression-free survival for NKTR-255 plus CD19-22CAR-T cell therapy at 12 months was double that of historical controls  –。SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ --Nektar Therapeutics  today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor -T cell therapy targeting CD19 and CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia  in Blood, the peer-reviewed medical journal of the American Society of Hematology.The primary outcomes of this study were feasibility and safety.Secondary endpoints were assessed for patients who received NKTR-255 (n=9) and included pharmacokinetics of NKTR-255 as measured by IL-15 levels in blood and efficacy as measured by remission free survival . Exploratory endpoints included cytokine profiling, CAR19-22 expansion in blood, bone marrow, and cerebrospinal fluid , and long-term CAR-T persistence.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-announces-publication-blood-phase-160700278.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-announces-publication-blood-phase-160700278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKTR","BK4007","BK4230","BK4022","CSF","CAR"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"},{"date":"2024-10-08","symbol":"CSF","amount":0.052247,"announcedDate":"2024-10-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-10-08","defaultRemindTime":1728394200000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-09","payableDate":"2024-10-08","currency":"USD","dateTimestamp":1728360000000,"payDate":"2024-10-09"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-16","recordDate":"2015-06-18","paymentDate":"2015-06-19","value":0.0849404,"currency":"USD"},{"executeDate":"2015-09-22","recordDate":"2015-09-24","paymentDate":"2015-09-25","value":0.0863264,"currency":"USD"},{"executeDate":"2015-12-28","recordDate":"2015-12-30","paymentDate":"2015-12-31","value":0.1258576,"currency":"USD"},{"executeDate":"2016-03-08","recordDate":"2016-03-10","paymentDate":"2016-03-11","value":0.0228347,"currency":"USD"},{"executeDate":"2016-06-14","recordDate":"2016-06-16","paymentDate":"2016-06-17","value":0.0798989,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{}}}